- Home
- CALC vs MDCX Comparison
CALC vs MDCX Comparison
Compare CALC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- MDCX
- Stock Information
- Founded
- CALC 2011
- MDCX 2008
- Country
- CALC United States
- MDCX Canada
- Employees
- CALC N/A
- MDCX N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- MDCX
- Sector
- CALC Health Care
- MDCX
- Exchange
- CALC Nasdaq
- MDCX Nasdaq
- Market Cap
- CALC 22.9M
- MDCX 44.0M
- IPO Year
- CALC N/A
- MDCX N/A
- Fundamental
- Price
- CALC $2.13
- MDCX $3.10
- Analyst Decision
- CALC Strong Buy
- MDCX Strong Buy
- Analyst Count
- CALC 2
- MDCX 2
- Target Price
- CALC $14.50
- MDCX $23.50
- AVG Volume (30 Days)
- CALC 38.7K
- MDCX 480.6K
- Earning Date
- CALC 08-11-2025
- MDCX 08-22-2025
- Dividend Yield
- CALC N/A
- MDCX N/A
- EPS Growth
- CALC N/A
- MDCX N/A
- EPS
- CALC N/A
- MDCX N/A
- Revenue
- CALC N/A
- MDCX N/A
- Revenue This Year
- CALC N/A
- MDCX N/A
- Revenue Next Year
- CALC N/A
- MDCX N/A
- P/E Ratio
- CALC N/A
- MDCX N/A
- Revenue Growth
- CALC N/A
- MDCX N/A
- 52 Week Low
- CALC $1.42
- MDCX $1.80
- 52 Week High
- CALC $5.97
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- CALC 48.14
- MDCX N/A
- Support Level
- CALC $1.59
- MDCX N/A
- Resistance Level
- CALC $1.69
- MDCX N/A
- Average True Range (ATR)
- CALC 0.15
- MDCX 0.00
- MACD
- CALC 0.01
- MDCX 0.00
- Stochastic Oscillator
- CALC 46.51
- MDCX 0.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.